Last reviewed · How we verify

Hib (Hiberix™) — Competitive Intelligence Brief

Hib (Hiberix™) (Hib (Hiberix™)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Conjugate vaccine. Area: Immunology / Infectious Disease.

phase 3 Conjugate vaccine Haemophilus influenzae type b polysaccharide capsule (PRP) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Hib (Hiberix™) (Hib (Hiberix™)) — GlaxoSmithKline. Hiberix is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) polysaccharide capsule.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Hib (Hiberix™) TARGET Hib (Hiberix™) GlaxoSmithKline phase 3 Conjugate vaccine Haemophilus influenzae type b polysaccharide capsule (PRP)
Prevnar 20 pneumococcal 20-valent conjugate vaccine (PCV20) Pfizer Inc. marketed Pneumococcal conjugate vaccine Streptococcus pneumoniae capsular polysaccharides (20 serotypes) 2021-06-08
pneumococcal conjugate 13 valent vaccine pneumococcal conjugate 13 valent vaccine University of Siena marketed Conjugate vaccine Streptococcus pneumoniae capsular polysaccharides (13 serotypes)
Menjugate® Menjugate® GlaxoSmithKline marketed Meningococcal conjugate vaccine Meningococcal serogroup C polysaccharide capsule
Hib conjugate vaccine Hib conjugate vaccine Public Health England marketed Conjugate vaccine Haemophilus influenzae type b polysaccharide capsule
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Sanofi Pasteur, a Sanofi Company marketed Conjugate vaccine Neisseria meningitidis polysaccharide capsule
NeisVac-C® NeisVac-C® Merck Sharp & Dohme LLC marketed Meningococcal conjugate vaccine Neisseria meningitidis serogroup C polysaccharide capsule

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Conjugate vaccine class)

  1. GlaxoSmithKline · 26 drugs in this class
  2. Sanofi Pasteur, a Sanofi Company · 6 drugs in this class
  3. CanSino Biologics Inc. · 3 drugs in this class
  4. MCM Vaccines B.V. · 3 drugs in this class
  5. Beijing Minhai Biotechnology Co., Ltd · 3 drugs in this class
  6. Wyeth is now a wholly owned subsidiary of Pfizer · 2 drugs in this class
  7. PT Bio Farma · 2 drugs in this class
  8. LG Life Sciences · 2 drugs in this class
  9. Walvax Biotechnology Co., Ltd. · 2 drugs in this class
  10. Heinrich-Heine University, Duesseldorf · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hib (Hiberix™) — Competitive Intelligence Brief. https://druglandscape.com/ci/hib-hiberix. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: